Vikas Goyal, MBA, promoted to Partner to lead growth stage investments in late preclinical and clinical stage biotechnology companies. BOSTON, MASSACHUSETTS / ACCESS Newswire / May 12, 2025 / Longwood ...

The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

Genmab Announces Financial Results for the First Quarter of 2024May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025HighlightsEPKINLY® (epcoritamab) approved by ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...

Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...